Oxyntomodulin (bovine, dog, porcine) trifluoroacetate salt

Modify Date: 2024-02-08 16:00:30

Oxyntomodulin (bovine, dog, porcine) trifluoroacetate salt structure	Common Name	Oxyntomodulin (bovine, dog, porcine) trifluoroacetate salt
	CAS Number	74870-06-7	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Oxyntomodulin (bovine, dog, porcine) trifluoroacetate salt

Oxyntomodulin (swine) is a dual agonist for GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), a peptide hormone released from the gut in post-prandial state. Oxyntomodulin (swine) suppresses appetite and reduces food intake[1][2][3].

Name	GLUCAGON (1-37) (PORCINE)

Description	Oxyntomodulin (swine) is a dual agonist for GLP-1 receptor (GLP-1R) and glucagon receptor (GCGR), a peptide hormone released from the gut in post-prandial state. Oxyntomodulin (swine) suppresses appetite and reduces food intake[1][2][3].
Related Catalog	Research Areas >> Metabolic Disease Research Areas >> Neurological Disease
In Vitro	Oxyntomodulin (0-1000 nM; 24 or 48 h) promotes neural cell proliferation in a dose- and time-dependent manner[3]. Oxyntomodulin (0-1000 nM; 24 h) protects against glutamate toxicity and oxidative stress in neuronal cells[3]. Oxyntomodulin (100 nM; 24 h) reduces glutamate-mediated neurotoxicity in primary cortical neurons in a dose-dependent manner[3]. Cell Proliferation Assay[3] Cell Line: SH-SY5Y and SH-hGLP-1R #9 cells Concentration: 0, 1, 10, 100, 1000 nM Incubation Time: 24 or 48 h Result: Increased cell viabilities at 24 h after treatment in hGLP-1R overexpressing #9 cells. Enhanced cell viability in both SH-SY5Y and #9 cells at 48 h after treatment.
In Vivo	Oxyntomodulin (intracerebroventricular administration; 20 μg per rat; once) treatment improves locomotor activity in stroke rats, and reduces cerebral infarction[3]. Animal Model: Transient middle cerebral artery occlusion (MCAo) rat model[3] Dosage: 20 μg per rat Administration: Intracerebroventricular administration; 20 μg per rat; once Result: Increased horizontal activity, movement number, movement time, total distance travelled, vertical activity, vertical movement number, and vertical movement time, compared to vehicle control group. Reduced the extent of cortical infarction compared to vehicle control group.